AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.

@article{Agteren2008AcylMPAGPC,
  title={AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.},
  author={Madelon van Agteren and Victor William Armstrong and Ron H. N. van Schaik and Hans J W de Fijter and Anders Hartmann and Martin G. Zeier and Klemens Budde and Dirk Kuypers and Przemyslav Pisarski and Yannick Le Meur and Marloes van der Werf and Richard D. Mamelok and Michael Oellerich and Teun van Gelder},
  journal={Therapeutic drug monitoring},
  year={2008},
  volume={30 4},
  pages={439-44}
}
Mycophenolic acid (MPA) is metabolized primarily by glucuronidation to form the biologically inactive 7-O-glucuronide conjugate (MPAG), which is the major urinary excretion product. MPA is also converted to acyl-glucuronide metabolite (AcylMPAG), which has been suggested to be involved in the generation of MPA-related adverse events such as diarrhea or leucopenia. This conversion of MPA to AcylMPAG is catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). We studied the impact of the -840G>A… CONTINUE READING
22 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…